Vaccinia virus (ATCC® VR-2046)

Classification: Poxviridae, Orthopoxvirus  /  Product Format: frozen

Classification Poxviridae, Orthopoxvirus
Agent Vaccinia virus
Strain vP-12
Biosafety Level 2
Isolation
A BglII fragment with the hepatitis B virus pre-surface antigen was cloned into the vaccinia vector VTK-79 (ATCC VR-2031) by in vivo recombination.
Product Format frozen
Storage Conditions -70°C
Comments
vP-11 (ATCC VR-2045) and vP-12 (ATCC VR-2046) contain the same insert but in opposite orientations.
Recombinant vaccinia containing genes for hepatitis B surface antigen.
A BglII fragment with the hepatitis B virus pre-surface antigen was cloned into the vaccinia vector VTK-79 (ATCC VR-2031) by in vivo recombination.
Effect on Host
Yes, in vitro effects: Cytopathic effects in tissue culture
Effect on Host
Yes, in vitro effects: Cytopathic effects in tissue culture
Name of Depositor E Paoletti
References

Paoletti E, Panicali D. Modified vaccinia virus. US Patent 4,603,112 dated Jul 29 1986

Paoletti E, Panicali D. Method for immunizing animals with synthetically modified vaccinia virus. US Patent 4,722,848 dated Feb 2 1988

Panicali D, et al. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J. Virol. 37: 1000-1010, 1981. PubMed: 6262520

Vaccination recommended for laboratory staff manipulating vaccinia, monkeypox, or cowpox viruses [CDC/NIH Biosafety in Microbiological and Biomedical Laboratories, 4th ed, 1999 - stock no. 017-040-00547-4].